← FDA DRUG APPROVALS

FDA NDA · NDA021424

NEURONTIN

Sponsor: PARKE DAVIS

APPLICATION
NDA021424
TYPE
NDA
ORIGINAL APPROVAL
2002-05-24
LATEST ACTION
2002-05-24
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

NEURONTINPrescription
GABAPENTIN 250MG/5ML · SOLUTION · ORAL

Approval history

2002-05-24Type 6 - New Indication (no longer used) · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →